CANY
PRCT icon

Caxton Associates (New York)’s Procept Biorobotics PRCT Stock Holding History

Caxton Associates (New York)’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-7,033
Closed -$430K – 628
2024
Q2 		$430K Buy
+7,033
New +$418K 0.01% 354

Other funds holding PRCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Caxton Associates (New York)'s PRCT Position: Q3 2024 in Review

Caxton Associates (New York) sold out of Procept Biorobotics (PRCT) in Q3 2024, closing a stake of 7,033 shares — an estimated $430K sold.

Caxton Associates (New York) first reported a position in PRCT in Q2 2024 and held it in 1 quarter. The position peaked at $430K in Q2 2024. 250 funds tracked by Wall St. Rank hold PRCT as of Q3 2024.

  • Caxton Associates (New York) reported no remaining Procept Biorobotics position as of Q3 2024 after selling out during the quarter.
  • Caxton Associates (New York) sold 7,033 Procept Biorobotics shares in Q3 2024, an estimated $430K.
  • Caxton Associates (New York) first reported a position in Procept Biorobotics in Q2 2024 and held it in 1 quarter.
  • Caxton Associates (New York)'s Procept Biorobotics position peaked at $430K in Q2 2024.
  • 250 funds tracked by Wall St. Rank held Procept Biorobotics as of Q3 2024.

Based on Caxton Associates (New York)'s 13F filing for Q3 2024, filed 14 Nov 2024.